Trial reportTransfusion medicine (Oxford, England)2025
Red blood cell transfusion practices in extracorporeal membrane oxygenation: A single-center study.
Trial report in Transfusion medicine (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Red blood cell transfusion practices in extracorporeal membrane oxygenation: A single-center study.Transfusion medicine (Oxford, England) · 2025Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesEvaluating blood transfusion practices and their impact on morbidity and mortality across extracorporeal membrane oxygenation (ECMO) configurations.
backgroundAs ECMO becomes increasingly utilised in critical care, the ideal Hgb level remains uncertain. While guidelines recommend higher levels, emerging evidence suggests potential harm. Our study addresses this gap by investigating the optimal Hgb level for ECMO.
methodsA retrospective cohort study included all adult patients receiving ECMO between January 2016 and December 2018. The primary outcome assessed the optimal Hgb level associated with reduced ECMO duration and in-hospital mortality. Multivariable and Cox-proportional regression analyses were performed.
resultsA total of 306 patients underwent ECMO, with 31 patients having mean Hgb levels 7-7.9 g/dL, 176 patients 8-8.9 g/dL, 72 patients 9-9.9 g/dL, and 27 patients ≥10 g/dL. The mean (SD) age was 56 years (15), with 60.8% male (186/306). ECMO configurations were primarily Venoarterial (VA) (59.8%), followed by Venovenous (VV) (36.9%) and Hybrid (3.3%). The 7-7.9 g/dL Hgb group was associated with longer ECMO duration (mean 17.5 days, coefficient 2.2, 95% CI 0.02-4.4, p = 0.048) compared to the ≥10 g/dL group, with no significant mortality differences across Hgb levels. VA ECMO patients had a significantly higher mortality risk than VV ECMO patients (aHR 2.33, 95% CI 1.50-3.60, p < 0.001). Blood product use, including RBC and Cryo, was associated with longer ECMO duration, while FFP reduced both duration (coefficient - 0.84, 95% CI -1.11--0.57, p < 0.001) and mortality risk (aHR 0.895, 95% CI 0.818-0.973, p = 0.012).
conclusionTargeting Hgb level >8 g/dL in ECMO patients may help reduce ECMO duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.